Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
Products for Apoptosis
- Caspase(99)
- 14.3.3 Proteins(1)
- Apoptosis Inducers(43)
- Bax(7)
- Bcl-2 Family(120)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(66)
- MDM2(12)
- p53(123)
- PC-PLC(4)
- PKD(7)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(145)
- Other Apoptosis(883)
- APC(6)
- PD-1/PD-L1 interaction(90)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(31)
- Cat.No. 产品名称 Information
-
GC10405
Methotrexate
甲氨蝶呤; Amethopterin; CL14377; WR19039
甲氨蝶呤(Methotrexate)是一种抗叶酸类抗代谢药,有效抑制二氢叶酸还原酶(DHFR)活性,IC50约为7nM。 -
GC13614
Mycophenolate Mofetil
吗替麦考酚酯; RS 61443; TM-MMF
A prodrug form of mycophenolic acid -
GC14921
CPI-613
6,8-双(苄硫基)辛酸,CPI-613
An inhibitor of α-ketoglutarate dehydrogenase -
GC17074
Tadalafil
他达那非; IC-351
A PDE5 inhibitor -
GC17685
Sildenafil Citrate
西地那非柠檬酸盐; UK-92480 citrate
A PDE5 inhibitor -
GC10420
Apremilast (CC-10004)
阿普司特; CC-10004
An orally available PDE4 inhibitor -
GC10153
Sabutoclax
BI-97C1
A pan-Bcl-2 inhibitor -
GC14080
Apogossypolone (ApoG2)
ApoG2
Apogossypolone (ApoG2) (ApoG2) 是一种具有口服活性的 Bcl-2 家族蛋白抑制剂,对 Bcl-2、Mcl-1 和 Bcl-XL 的 Ki 值分别为 35、25 和 660 nM。 -
GC13383
EPZ004777
EPZ004777 作为一种有效的表观遗传调节剂,可以逆转 TGF-β1 诱导的 T 调节细胞,可用于治疗多种免疫疾病。
-
GC11569
Obatoclax mesylate (GX15-070)
Obatoclax甲磺酸盐,GX15-070 Mesylate
An antagonist of pro-survival Bcl-2 proteins -
GC13498
BM-1074
BM-1074 是一种有效且特异性的 Bcl-2/Bcl-xL 抑制剂,对 Bcl-2 和 Bcl-xL 的 Ki 值 < 1 nM,IC50 值分别为 1.8 nM 和 6.9 nM。 BM-1074 诱导细胞凋亡,并对四种小细胞肺癌细胞系(H146、H1963、H187 和 H1417)具有抗增殖活性,IC50 值为 1-2 nM。
-
GC12793
RITA (NSC 652287)
5,5'-(2,5-呋喃二基)二-2-噻吩甲醇,NSC 652287
An inhibitor of the p53-HDM-2 interaction -
GC14165
Tenovin-1
A small molecule activator of p53
-
GC12117
JNJ-26854165 (Serdemetan)
N-[2-(1H-吲哚-3-基)乙基]-N'-(4-吡啶基)-1,4-苯二胺,JNJ 26854165
An antagonist of MDM2 action -
GC10538
Pifithrin-α (PFTα)
2-(2-亚氨基-4,5,6,7-四氢苯并噻唑-3-基)-1-P-甲苯基乙酮氢溴酸盐,Pifithrin hydrobromide; PFTα hydrobromide
Pifithrin-α是一种p53抑制剂。 -
GC16391
Amuvatinib (MP-470, HPK 56)
N-(1,3-苯并二氧戊环-5-基甲基)-4-苯并呋喃并[3,2-D]嘧啶-4-基-1-哌嗪硫代甲酰胺,MP470,MP 470,HPK56
A multi-targeted RTK inhibitor -
GC12649
TW-37
N-[4-(2-叔丁基苯磺酰基)苯基]-2,3,4-三羟基-5-(2-异丙基苯基甲基)苯甲酰胺,TW37,TW 37
An inhibitor of the Bcl-2 family proteins -
GC13687
NSC 66811
7-(ALPHA-苯胺基苄基)-2-甲基-8-喹啉醇
A potent inhibitor of Mdm2-p53 interaction -
GC16051
Nutlin-3
4-[[4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-基]羰基]-2-哌嗪酮,Nutlin 3,MDM2 Antagonist
A racemic mixture of (?)-nutlin-3 and (+)-nutlin-3 -
GC14451
GDC-0152
GDC0152, GDC 0152
An inhibitor of IAPs -
GC13107
YM155
4,9-二氢-1-(2-甲氧基乙基)-2-甲基-4,9-二氧代-3-(2-吡嗪甲基)-1H-萘并[2,3-D]咪唑溴化物,Sepantronium bromide,YM-155
A small molecule survivin suppressant -
GC12426
Birinapant (TL32711)
比瑞那帕; TL32711
Birinapant (TL32711) 是一种 SMAC 模拟物,旨在专门针对 cIAP1 和 cIAP2 进行降解。
-
GC11751
QNZ (EVP4593)
N4-[2-(4-苯氧基苯基)乙基]-4,6-喹唑啉二胺,EVP4593
An inhibitor of NF-κB activation -
GC17054
Thalidomide
沙利度胺
An immunomodulatory compound with diverse biological activities -
GC11008
Necrostatin-1
MTH-DL-Tryptophan,Nec-1
Necrostatin-1主要作用于细胞中的RIP1,Necrostatin-1是一种RIP1激酶抑制剂,IC50值为0.32 mM。 -
GC11697
Pomalidomide (CC-4047)
泊马度胺; CC-4047
An inhibitor of cereblon -
GC14976
Lenalidomide (CC-5013)
来那度胺; CC-5013
An analog of thalidomide -
GC13035
Bay 11-7821
BAY 11-7082
Bay 11-7821(BAY 11-7082)是一种IκBα磷酸化和NF-κB抑制剂,选择性且不可逆地抑制TNF-α诱导的IκB-α磷酸化(IC50值约为10μM),并减少NF-κB和粘附分子的表达。Bay 11-7821抑制泛素特异性蛋白酶USP7和USP21,IC50分别为0.19、0.96μM。 -
GC12701
NSC 207895 (XI-006)
4-(4-甲基-1-哌嗪基)-7-硝基-2,1,3-苯并二唑3-氧化物,XI-006
An inhibitor of MDMX -
GC15404
NSC 319726
ZMC1
A p53 reactivator -
GC10008
GSK1070916
GSK-1070916A
A potent inhibitor of Aurora B and C kinases -
GC13332
Aurora A Inhibitor I
A potent and selective inhibitor of Aurora A kinase
-
GC14592
KW 2449
[4-[2-(1H-吲唑-3-基)乙烯基]苯基]-1-哌嗪基甲酮
A multi-kinase inhibitor -
GC10638
AT9283
A broad spectrum kinase inhibitor
-
GC15217
Danusertib (PHA-739358)
达鲁舍替,5-Amido-pyrrolopyrazole 9d
A pan-Aurora kinase and Abl inhibitor -
GC12612
JNJ-7706621
JNJ7706621, JNJ 7706621
A dual inhibitor of CDKs and Aurora kinases -
GC17303
Ritonavir
利托那韦; ABT 538; RTV
An HIV protease inhibitor -
GC14590
AR-42 (OSU-HDAC42)
HDAC inhibitor,novel and potent
-
GC13408
CI994 (Tacedinaline)
4-乙酰氨基-N-(2'-氨基苯基)-苯甲酰胺,N-acetyldinaline; CI-994; Goe-5549
An inhibitor of HDAC1, -2, and -3 -
GC10839
Tubastatin A
Tubastatin A 是一种有效的选择性 HDAC6 抑制剂,IC50 值为 15 nM。并且Tubastatin A也是一种新型GPX4抑制剂,Tubastatin A 直接与 GPX4 结合,诱导乳腺癌细胞铁死亡。
-
GC13706
Droxinostat
4-(4-氯-2-甲基苯氧基)-N-羟基丁酰胺,NS 41080
An inhibitor of HDAC3, HDAC6, and HDAC8 -
GC12115
CUDC-907
CUDC-907
CUDC 是一种口服生物可利用的小分子 PI3K 和 HDAC 双重抑制剂,作用于 PI3K α 和 HDAC1 / 2 / 3 / 10,IC50 分别为 19 nm 和 1.7 nm / 5 nm / 1.8 nm / 2.8 nm .在 WSU DLCL2 细胞中评估了双功能 HDAC 和 PI3K 抑制剂 CUDC-907 的抗肿瘤活性。 -
GC16734
Pracinostat (SB939)
(2E)-3-[2-丁基-1-[2-(二乙基氨基)乙基]-1H-苯并咪唑-5-基]-N-羟基丙烯酰胺,SB-939, SB 939
A pan-HDAC inhibitor
-
GC16733
Vildagliptin (LAF-237)
维格列汀; LAF237; NVP-LAF 237
A DPP-4 inhibitor -
GC14566
CCT137690
甲磺酸阿贝西尼
An inhibitor of Aurora kinases and FLT3 -
GC16519
ENMD-2076
6-(4-甲基-1-哌嗪基)-N-(5-甲基-1H-吡唑-3-基)-2-[(1E)-2-苯乙烯基]-4-嘧啶胺
A multi-kinase inhibitor -
GC14409
ZM 447439
Selective inhibitor of Aurora B kinase
-
GC12690
MLN8237 (Alisertib)
阿立塞替,MLN 8237
Alisertib (MLN8237) 作为一种在研、可口服的选择性极光 A 激酶抑制剂,通常用于治疗实体瘤和血液系统恶性肿瘤。 -
GC15002
Sodium Phenylbutyrate
苯丁酸钠; 4-PBA sodium; 4-Phenylbutyric acid sodium; Benzenebutyric acid sodium
A chemical chaperone -
GC15315
Scriptaid
Scriptide; GCK1026
HDAC inhibitor